**Serial Number:** 09/852,424     0590  1023     CRF Processing Date: 10-25-01 #7
Edited by: M. Spencer
Verified by: _____ (STIC staff)

☐ Changed a file from non-ASCII to ASCII

☐ Changed the margins in cases where the sequence text was "wrapped" down to the next line.

☐ Edited a format error in the Current Application Data section, specifically:
OIP L
**ENTERED**
_____

☐ Edited the Current Application Data section with the actual current number. The number inputted by the applicant was ☐ the prior application data; or ☐ other _____.

☐ Added the mandatory heading and subheadings for "Current Application Data".

☐ Edited the "Number of Sequences" field. The applicant spelled out a number instead of using an integer.

☐ Changed the spelling of a mandatory field (the headings or subheadings), specifically:
_____

☐ Corrected the SEQ ID NO when obviously incorrect. The sequence numbers that were edited were:
_____

☐ Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited:
_____

☐ Corrected subheading placement. All responses must be on the same line as each subheading. If the applicant placed a response below the subheading, this was moved to its appropriate place.

☐ Inserted colons after headings/subheadings. Headings edited included:
_____

☐ Deleted extra, invalid, headings used by an applicant, specifically:
_____

☑ Deleted: ☑ non-ASCII "garbage" at the beginning/end of files; ☐ secretary initials/filename at end of file; ☐ page numbers throughout text; ☐ other invalid text, such as_____.

☐ Inserted mandatory headings, specifically: _____

☐ Corrected an obvious error in the response, specifically:
_____

☐ Edited identifiers where upper case is used but lower case is required, or vice versa.

☐ Corrected an error in the Number of Sequences field, specifically:
_____

☐ A "Hard Page Break" code was inserted by the applicant. All occurrences had to be deleted.

☐ Deleted *ending* stop codon in amino acid sequences and adjusted the "(A)Length:" field accordingly (error due to a PatentIn bug). Sequences corrected: _____

☐ Other:
_____
_____
_____

**\*Examiner: The above corrections must be communicated to the applicant in the first Office Action. DO NOT send a copy of this form.**
3/1/95

OIPE

RAW SEQUENCE LISTING                    DATE: 10/25/2001
PATENT APPLICATION:  US/09/852,424      TIME: 13:56:18

Input Set : A:\pto_ms.txt
Output Set: N:\CRF3\10252001\I852424.raw

```
 3 <110> APPLICANT: The University of British Columbia; and
 4       Chemokine Therapeutics Corporation
 6 <120> TITLE OF INVENTION: CXCR4 ANTAGONIST TREATMENT OF HEMATOPOIETIC CELLS
 8 <130> FILE REFERENCE: 80021-257
10 <140> CURRENT APPLICATION NUMBER: US 09/852,424
11 <141> CURRENT FILING DATE: 2001-09-26
13 <150> PRIOR APPLICATION NUMBER: CA 2,305,787
14 <151> PRIOR FILING DATE: 2000-05-09
16 <150> PRIOR APPLICATION NUMBER: US 60/205,467
17 <151> PRIOR FILING DATE: 2000-05-19
19 <160> NUMBER OF SEQ ID NOS: 135
21 <170> SOFTWARE: PatentIn Ver. 2.0
23 <210> SEQ ID NO: 1
24 <211> LENGTH: 67
25 <212> TYPE: PRT
26 <213> ORGANISM: Artificial Sequence
28 <220> FEATURE:
29 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
30       Laboratory
32 <400> SEQUENCE: 1
33 Lys Gly Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
34  1               5                  10                  15
36 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
37              20                  25                  30
39 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
40          35                  40                  45
42 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
43      50                  55                  60
45 Ala Leu Asn
46  65
49 <210> SEQ ID NO: 2
50 <211> LENGTH: 67
51 <212> TYPE: PRT
52 <213> ORGANISM: Artificial Sequence
54 <220> FEATURE:
55 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
56       Laboratory
58 <400> SEQUENCE: 2
59 Lys Gly Val Ser Pro Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
60  1               5                  10                  15
62 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
63              20                  25                  30
65 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
66          35                  40                  45
68 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
69      50                  55                  60
71 Ala Leu Asn
```

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/852,424

DATE: 10/25/2001
TIME: 13:56:18

Input Set : A:\pto_ms.txt
Output Set: N:\CRF3\10252001\I852424.raw

```
72  65
75 <210> SEQ ID NO: 3
76 <211> LENGTH: 67
77 <212> TYPE: PRT
78 <213> ORGANISM: Artificial Sequence
80 <220> FEATURE:
81 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
82       Laboratory
84 <400> SEQUENCE: 3
85 Lys Gly Val Ser Leu Pro Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
86  1               5               10                  15
88 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
89             20                  25                  30
91 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
92         35                  40                  45
94 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
95      50                  55                  60
97 Ala Leu Asn
98  65
101 <210> SEQ ID NO: 4
102 <211> LENGTH: 67
103 <212> TYPE: PRT
104 <213> ORGANISM: Artificial Sequence
106 <220> FEATURE:
107 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
108       Laboratory
110 <400> SEQUENCE: 4
111 Lys Gly Val Ser Leu Ser Pro Arg Cys Pro Cys Arg Phe Phe Glu Ser
112  1               5               10                  15
114 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
115             20                  25                  30
117 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
118         35                  40                  45
120 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
121      50                  55                  60
123 Ala Leu Asn
124  65
127 <210> SEQ ID NO: 5
128 <211> LENGTH: 67
129 <212> TYPE: PRT
130 <213> ORGANISM: Artificial Sequence
132 <220> FEATURE:
133 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
134       Laboratory
136 <400> SEQUENCE: 5
137 Lys Gly Val Ser Leu Ser Tyr Pro Cys Pro Cys Arg Phe Phe Glu Ser
138  1               5               10                  15
140 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
141             20                  25                  30
```

RAW SEQUENCE LISTING                    DATE: 10/25/2001
PATENT APPLICATION:   US/09/852,424     TIME: 13:56:18

Input Set : A:\pto_ms.txt
Output Set: N:\CRF3\10252001\I852424.raw

```
    143 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
    144         35              40                  45
    146 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
    147         50              55                  60
    149 Ala Leu Asn
    150  65
    153 <210> SEQ ID NO: 6
    154 <211> LENGTH: 67
    155 <212> TYPE: PRT
    156 <213> ORGANISM: Artificial Sequence
    158 <220> FEATURE:
    159 <221> NAME/KEY: MUTAGEN
    160 <222> LOCATION: (5)
    161 <223> OTHER INFORMATION: Xaa=P*=proline-amino acid chimera. See page 17 of
    162       disclosure for possible structures for P*
    164 <220> FEATURE:
    165 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
    166       Laboratory
    168 <400> SEQUENCE: 6
W--> 169 Lys Gly Val Ser Xaa Ser Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
    170  1               5                  10                  15
    172 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
    173         20              25                  30
    175 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
    176         35              40                  45
    178 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
    179         50              55                  60
    181 Ala Leu Asn
    182  65
    185 <210> SEQ ID NO: 7
    186 <211> LENGTH: 67
    187 <212> TYPE: PRT
    188 <213> ORGANISM: Artificial Sequence
    190 <220> FEATURE:
    191 <221> NAME/KEY: MUTAGEN
    192 <222> LOCATION: (6)
    193 <223> OTHER INFORMATION: Xaa=P*=proline-amino acid chimera. See page 17 of
    194       disclosure for possible structures for P*
    196 <220> FEATURE:
    197 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
    198       Laboratory
    200 <400> SEQUENCE: 7
W--> 201 Lys Gly Val Ser Leu Xaa Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser
    202  1               5                  10                  15
    204 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
    205         20              25                  30
    207 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
    208         35              40                  45
    210 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
```

RAW SEQUENCE LISTING                    DATE: 10/25/2001
PATENT APPLICATION: US/09/852,424       TIME: 13:56:18

Input Set : A:\pto_ms.txt
Output Set: N:\CRF3\10252001\I852424.raw

```
211       50                  55              60
213 Ala Leu Asn
214  65
217 <210> SEQ ID NO: 8
218 <211> LENGTH: 67
219 <212> TYPE: PRT
220 <213> ORGANISM: Artificial Sequence
222 <220> FEATURE:
223 <221> NAME/KEY: MUTAGEN
224 <222> LOCATION: (7)
225 <223> OTHER INFORMATION: Xaa=P*=proline-amino acid chimera. See page 17 of
226       disclosure for possible structures for P*
228 <220> FEATURE:
229 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
230       Laboratory
232 <400> SEQUENCE: 8
```
W--> 233 Lys Gly Val Ser Leu Ser Xaa Arg Cys Pro Cys Arg Phe Phe Glu Ser
```
234  1               5                 10                  15
236 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
237              20                  25                  30
239 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
240          35                  40                  45
242 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
243       50                  55                  60
245 Ala Leu Asn
246  65
249 <210> SEQ ID NO: 9
250 <211> LENGTH: 67
251 <212> TYPE: PRT
252 <213> ORGANISM: Artificial Sequence
254 <220> FEATURE:
255 <221> NAME/KEY: MUTAGEN
256 <222> LOCATION: (8)
257 <223> OTHER INFORMATION: Xaa=P*=proline-amino acid chimera. See page 17 of
258       disclosure for possible structures for P*
260 <220> FEATURE:
261 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
262       Laboratory
264 <400> SEQUENCE: 9
```
W--> 265 Lys Gly Val Ser Leu Ser Tyr Xaa Cys Pro Cys Arg Phe Phe Glu Ser
```
266  1               5                 10                  15
268 His Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro
269              20                  25                  30
271 Asn Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln
272          35                  40                  45
274 Val Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys
275       50                  55                  60
277 Ala Leu Asn
278  65
```

RAW SEQUENCE LISTING                    DATE: 10/25/2001
PATENT APPLICATION:  US/09/852,424      TIME: 13:56:18

Input Set : A:\pto_ms.txt
Output Set: N:\CRF3\10252001\I852424.raw

```
281 <210> SEQ ID NO: 10
282 <211> LENGTH: 66
283 <212> TYPE: PRT
284 <213> ORGANISM: Artificial Sequence
286 <220> FEATURE:
287 <221> NAME/KEY: MUTAGEN
288 <222> LOCATION: (5)
289 <223> OTHER INFORMATION: Xaa=Btd=Bicyclic Turned Dipeptide. See Page 17 of
290       disclosure for possible structures for Btd
292 <220> FEATURE:
293 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
294       Laboratory
296 <400> SEQUENCE: 10
```
W--> 297 Lys Gly Val Ser Xaa Tyr Arg Cys Pro Cys Arg Phe Phe Glu Ser His
     298  1               5               10              15
     300 Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro Asn
     301          20              25              30
     303 Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln Val
     304          35              40              45
     306 Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala
     307      50              55              60
     309 Leu Asn
     310  65
```
313 <210> SEQ ID NO: 11
314 <211> LENGTH: 66
315 <212> TYPE: PRT
316 <213> ORGANISM: Artificial Sequence
318 <220> FEATURE:
319 <221> NAME/KEY: MUTAGEN
320 <222> LOCATION: (6)
321 <223> OTHER INFORMATION: Xaa=Btd=Bicyclic Turned Dipeptide. See Page 17
322       of disclosure for possible structures for Btd
324 <220> FEATURE:
325 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
326       Laboratory
328 <400> SEQUENCE: 11
```
W--> 329 Lys Gly Val Ser Leu Xaa Arg Cys Pro Cys Arg Phe Phe Glu Ser His
     330  1               5               10              15
     332 Val Ala Arg Ala Asn Val Lys His Leu Lys Ile Leu Asn Thr Pro Asn
     333          20              25              30
     335 Cys Ala Leu Gln Ile Val Ala Arg Leu Lys Asn Asn Asn Arg Gln Val
     336          35              40              45
     338 Cys Ile Asp Pro Lys Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala
     339      50              55              60
     341 Leu Asn
     342  65
```
345 <210> SEQ ID NO: 12
346 <211> LENGTH: 66
347 <212> TYPE: PRT
```

Use of n and / or Xaa has been detected in the
Sequence Listing. Review the Sequence Listing
to ensure a corresponding explanation is present
in the <220> to <223> fields of each sequence
using n or Xaa.

VERIFICATION SUMMARY                          DATE: 10/25/2001
PATENT APPLICATION:  US/09/852,424            TIME: 13:56:19

Input Set : **A:\pto_ms.txt**
Output Set: **N:\CRF3\10252001\I852424.raw**

```
L:11   M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:169  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:201  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:233  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:265  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9
L:297  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:329  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:361  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:448  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16
L:555  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:578  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:601  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:624  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:647  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:26
L:667  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27
L:687  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:28
L:763  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:783  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34
L:803  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35
L:823  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36
L:843  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37
L:863  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38
L:883  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39
L:999  M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:44
L:1027 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:45
L:1055 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46
L:1083 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47
L:1111 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48
L:1139 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:49
L:1167 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50
L:1189 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51
L:1230 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:53
L:1271 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:55
L:1312 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:57
L:1359 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:59
L:1384 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:60
L:1412 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:61
L:1437 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:62
L:1465 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:63
L:1490 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:64
L:1518 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:65
L:1543 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:66
L:1571 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:67
L:1596 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:68
L:1624 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:69
L:1649 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:70
L:1677 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:71
L:1702 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:72
```

**VERIFICATION SUMMARY**
PATENT APPLICATION:  **US/09/852,424**

DATE: 10/25/2001
TIME: 13:56:19

Input Set : **A:\pto_ms.txt**
Output Set: **N:\CRF3\10252001\I852424.raw**

```
L:1784 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:76
L:1809 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77
L:2024 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:86
```

```
RAW SEQUENCE LISTING                    DATE: 10/10/2001
PATENT APPLICATION:  US/09/852,424      TIME: 11:17:41

Input Set : A:\80021-257.us.sequence listing.txt
Output Set: N:\CRF3\10102001\I852424.raw

 3 <110> APPLICANT: The University of British Columbia; and
 4        Chemokine Therapeutics Corporation
 6 <120> TITLE OF INVENTION: CXCR4 ANTAGONIST TREATMENT OF HEMATOPOIETIC CELLS
 8 <130> FILE REFERENCE: 80021-257
10 <140> CURRENT APPLICATION NUMBER: US 09/852,424
```
C--> `11 <141> CURRENT FILING DATE: 2001-09-26`
```
13 <150> PRIOR APPLICATION NUMBER: CA 2,305,787
14 <151> PRIOR FILING DATE: 2000-05-09
16 <150> PRIOR APPLICATION NUMBER: US 60/205,467
17 <151> PRIOR FILING DATE: 2000-05-19
19 <160> NUMBER OF SEQ ID NOS: 135
21 <170> SOFTWARE: PatentIn Ver. 2.0
```

**Does Not Comply
Corrected Diskette Needed**

ERRORED SEQUENCES

```
3323 <210> SEQ ID NO: 135
3324 <211> LENGTH: 31
3325 <212> TYPE: PRT
3326 <213> ORGANISM: Artificial Sequence
3328 <220> FEATURE:
3329 <221> NAME/KEY: DOMAIN
3330 <222> LOCATION: (24)..(28)
3331 <223> OTHER INFORMATION: K28/E24 Lactamization - domain cyclized
3333 <220> FEATURE:
3334 <221> NAME/KEY: MOD_RES
3335 <222> LOCATION: (31)
3336 <223> OTHER INFORMATION: AMIDATION
3338 <220> FEATURE:
3339 <221> NAME/KEY: DOMAIN
3340 <222> LOCATION: (15)..(18)
3341 <223> OTHER INFORMATION: The number of glycines linking the N- and
3342        C-terminal amino acids may be varied.
3344 <220> FEATURE:
3345 <223> OTHER INFORMATION: Description of Artificial Sequence: Engineered in
3346        Laboratory
3348 <400> SEQUENCE: 135
3349 Lys Gly Val Ser Leu Ser Tyr Arg Cys Pro Cys Arg Phe Phe Gly Gly
3350  1           5                   10                  15
3352 Gly Gly Leu Lys Trp Ile Gln Glu Tyr Leu Glu Lys Ala Leu Asn
3353          20                  25                  30
```
E--> `3356 59`

*Delete miscellaneous material from end of file.*

Use of n and / or Xaa has been detected in the Sequence Listing. Review the Sequence Listing to ensure a corresponding explanation is present in the <220> to <223> fields of each sequence using n or Xaa.

VERIFICATION SUMMARY                    DATE: 10/10/2001
PATENT APPLICATION:  US/09/852,424      TIME: 11:17:42

Input Set : A:\80021-257.us.sequence listing.txt
Output Set: N:\CRF3\10102001\I852424.raw

```
L:11 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:169 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:201 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:233 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:265 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9
L:297 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:329 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:361 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:448 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16
L:555 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:578 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:601 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24
L:624 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25
L:647 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:26
L:667 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27
L:687 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:28
L:763 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33
L:783 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34
L:803 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35
L:823 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36
L:843 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37
L:863 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38
L:883 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39
L:999 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:44
L:1027 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:45
L:1055 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:46
L:1083 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:47
L:1111 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:48
L:1139 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:49
L:1167 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50
L:1189 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51
L:1230 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:53
L:1271 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:55
L:1312 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:57
L:1359 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:59
L:1384 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:60
L:1412 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:61
L:1437 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:62
L:1465 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:63
L:1490 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:64
L:1518 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:65
L:1543 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:66
L:1571 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:67
L:1596 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:68
L:1624 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:69
L:1649 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:70
L:1677 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:71
L:1702 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:72
```

VERIFICATION SUMMARY                    DATE: 10/10/2001
PATENT APPLICATION:   US/09/852,424     TIME: 11:17:42

      Input Set : A:\80021-257.us.sequence listing.txt
      Output Set: N:\CRF3\10102001\I852424.raw

```
L:1784 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:76
L:1809 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77
L:2024 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:86
L:3356 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:135
```